The influence of PON1 192 polymorphism on endothelial function in diabetic subjects with or without hypertension

Hypertension Research

Volumn 31, Issue 3, 2008, Pages 507-513

  Irace, Concetta ^a   Cortese, Claudio ^b   Fiaschi, Elio ^a   Scavelli, Faustina ^a   Liberatoscioli, Laura ^b   Federici, Giorgio ^b   Gnasso, Agostino ^a,c  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c Policlinico Mater Domini   (Italy)

Author keywords

Diabetes mellitus; Endothelial function; Genetic polymoprhism; Paraoxonase

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ARGININE; ARYLDIALKYLPHOSPHATASE 1; GLYCINE; HIGH DENSITY LIPOPROTEIN;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ANTIOXIDANT ACTIVITY; ARTICLE; BRACHIAL ARTERY; CODON; COMORBIDITY; CONTROLLED STUDY; DATA ANALYSIS; ENDOTHELIAL DYSFUNCTION; FEMALE; FOREARM; GENE AMPLIFICATION; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; HYPERTENSION; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; VASCULAR ENDOTHELIUM; VASODILATATION; VEIN BLOOD FLOW;

ALLELES; ARYLDIALKYLPHOSPHATASE; BLOOD PRESSURE; BRACHIAL ARTERY; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HOMOZYGOTE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OXIDATIVE STRESS; POLYMORPHISM, SINGLE NUCLEOTIDE; VASODILATION;

EID: 42649134522     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.507     Document Type: Article

References (34)

1. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA: Impaired nitric-oxide mediated vasodilatation in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol 1996; 27: 567-574.
2. Evans M, Anderson RA, Graham J, et al: Ciprofibrate therapy improves endothelial functionand reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2000; 101: 1773-1779.
3. Bagg W, Whalley GA, Gamble G, Drury PL, Sharpe N, Braatvedt GD: Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes. Intern Med J 2001; 31: 322-328.
4. Ravikumar R, Deepa R, Shanthirani C, Mohan V: Comparison of carotid intima-media thickness, arterial stiffness, and brachial artery flow mediated dilatation in diabetic and non-diabetic subjects (the Chennai Urban Population Study [CUPS-9]). Am J Cardiol 2002; 90: 702-707.
5. Kugiyama K, Kerns SA, Morisett JD, Roberts R, Henry PD: Impairment of endothelium-dependent arterial relaxation by lisolecithin in modified low-density lipoproteins. Nature 1990; 344: 160-162.
6. Simon BC, Cunningham LD, Cohen RA: Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest 1990; 86: 75-79.
7. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P: The effects of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-493.
8. Taskinen MR: Pathogenesis of dyslipidemia in type 2 diabetes: Exp Clin Endocrinol Diabetes 2001; 109: 180-188.
9. Tan KC, Ai VH, Chow WS, Chan MT, Leong L, Lam KS: Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes. J Clin Endocrinol Metab 1999; 84: 3212-3216.
10. Kopprasch S, Pietzsch J, Kuhlisch E, et al: In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes 2002; 51: 3102-3106.
11. Landmesser U, Drexler H: Endothelial function and hypertension. Curr Opin Cardiol 2007; 22: 316-320.
12. Mackness MI, Arrol S, Abbott CA, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-135.
13. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN: Effect of the human serum paraoxonase 55 and 192 genetic polymorphism on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998; 423: 57-60.
14. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parno SL, La Du B: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-1590.
15. Avirarn M, Hardak E, Vaya J, et al: Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000; 101: 2510-2517.
16. Mackness MJ, Arrol S, Mackness B, Durrington PN: Alloenzymes of paraoxonase and effectiveness of high density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet 1997; 349: 851-852.
17. Yamane T, Matsumoto T, Nakae I, et al: Impact of paraoxonase polymorphism (Q192R) on endothelial function in intact coronary circulation. Hypertens Res 2006; 29: 417-422.
18. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A: Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002; 62: 265-284.
19. Gnasso A, Motti C, Irace C, et al: The Arg allele in position 192 of PON1 is associated with carotid atherosclerosis in subjects with elevated HDLs. Atherosclerosis 2002; 164: 289-295.
20. Irace C, Ceravolo R, Notarangelo L, et al: Comparison of endothelial function evaluated by strain gauge plethysmography and brachial artery ultrasound. Atherosclerosis 2001; 158: 53-59.
21. Frei B: On the role of vitamin C and other antioxidants in atherogenesis and vascular dysfunction. Proc Soc Exp Biol Med 1999; 222: 196-204.
22. Paolisso G, Manzella D, Tagliamonte MR, et al: The BB-paraoxonase genotype is associated with impaired brachial reactivity after acute hypertriglyceridemia in healthy subjects. J Clin Endocrinol Metab 2001; 86: 1078-1082.
23. Tomiyama H, Kushiro T, Okazaki R, Yoshida H, Doba N, Yamashina A: Influences of increased oxidative stress on endothelial function, platelets function, and fibrinolysis in hypertension associated with glucose intolerance. Hypertens Res 2003; 26: 295-300.
24. Wheler JG, Keavney BD, Watkins H, Collins R, Danesh J: Four paraoxonase gene polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies. Lancet 2004; 363: 689-695.
25. Pfohl M, Koch M, Enderle MD, et al: Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 1999; 48: 623-627.
26. Ruiz J, Blanche H, James RW, et al: GIn-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869-872.
27. Cosentino F, Luscher TF: Effects of blood pressure and glucose on endothelial function. Curr Hypertens Rep 2001; 3: 79-88.
28. Richter RJ, Furlong CE: Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999; 9: 745-753.
29. Mackness B, Davies GK, Turkie W, et al: Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21: 1451-1457.
30. Mackness B, Durrington P, McElduff P, et al: Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003; 107: 2775-2779.
31. Crouse JR, Goldbourt U, Evans G, et al: Risk factors and segment-specific carotid arterial enlargement in the Atherosclerosis Risk in Communities (ARIC) Cohort. Stroke 1996; 27: 69-75.
32. Lambert J, Aarsen M, Donker AJ, Stehouwer CD: Endothelium-dependent and -independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16: 705-711.
33. Monnier VM, Kohn RR, Cerami A: Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci U S A 1984; 81: 583-587.
34. Wautier JL, Wautier MP, Schmidt AM, et al: Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 1994; 91: 7742-7746.